THIS PROJECT PROPOSES A COMPREHENSIVE APPROACH TO THIS PROBLEM BY: (1) THE DEVELOPMENT OF RADIOPHARMACEUTICALS FOR LIVE CANCER IMAGING AND THE IDENTIFICATION OF SPECIFIC MOLECULAR TARGETS FOR IMMUNOTHERAPY (PDÂ L1) OR FOR TREATMENT WITH TEST DRUGS (CXCR4), (2) THE DESIGN AND IMPLEMENTATION OF INNOVATIVE METHODS OF HIGH EFFICIENCY FOR THE ISOLATION AND MOLECULAR CHARACTERISATION OF CIRCULATING TUMOUR CELLS, AS A SURROGATE OF THE BIOPSY TESTS OBJECTIVE PURSUED THROUGH TWO COMPLEMENTARY APPROACHES, ONE DEDICATED TO MEDICAL IMAGING AND THE OTHER USING MICROSCOPY/IMAGING TECHNOLOGY CELLLULATRENIS CANCER DIAGNOSTICS, WHICH IS OFTEN ACHIEVED THROUGH ENOSCOPICHE, TRANSCUTANEOUS ASPIRATION OR SURGICAL OPERATION. THIS SIGNIFICANTLY LIMITS THE ABILITY OF CANCER PATIENTS AND ESPECIALLY THOSE WITH LUNG CANCER TO HAVE ACCESS TO APPROVED TREATMENTS IN CLINICAL OR TESTING PRACTICE IN CLIN.